BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 11, 2017
View Archived Issues
INCB-062079 shows potent and selective inhibition in models of FGF19-FGFR4-dependent cancers
Read More
Leptin receptor antagonist allo-aca reverses leptin-induced aggressive prostate cancer phenotype
Read More
BGS-649 normalizes testosterone levels in patients with secondary hypogonadotropic hypogonadism
Read More
Phase II YOSEMITE trial of demcizumab in pancreatic cancer does not meet primary endpoint
Read More
Bayer terminates its option to license vantictumab or ipafricept from OncoMed
Read More
Alzheimer's disease treatment candidate Q-134R inhibits NFATsignaling
Read More
Pfizer presents allosteric inhibitors of IL-2-inducible T-cell kinase for inflammatory diseases
Read More
Ovid Therapeutics starts phase I trial of gaboxadol in Angelman syndrome
Read More
FDA accepts Syros Pharmaceuticals's IND for SY-1365
Read More
FORMA Therapeutics meets two more objectives in Celgene collaboration
Read More
TherapeuticsMD gives update on TX-004HR NDA
Read More
Roche reports that phase III ALEX study of alectinib met its PFS endpoint
Read More
Redx Pharma patents tyrosine-protein kinase BTK inhibitors
Read More
GlaxoSmithKline divulges novel bromodomain and extra-terminal protein inhibitors
Read More
Pfizer discovers new beta-secretase 1 inhibitors
Read More
Janssen Pharmaceutica discloses novel fibroblast growth factor receptor inhibitors
Read More
Roche synthesizes novel E-NPP 2/CA-II inhibitors
Read More
CN Bio Innovations gains worldwide rights to hepatitis B program from Bristol-Myers Squibb
Read More
FDA sets PDUFA date for Zerviate NDA
Read More
Nippon Kayaku submits application for marketing approval of CT-P6 in Japan
Read More
FDA clears way for pilot trial of Cytori Cell Therapy in thermal burn injury
Read More
Ferring and Alrise Biosystems enter exclusive agreement
Read More
eFFECTOR Therapeutics selects Cancer Genetics to provide biomarker services for lead candidate
Read More
Geron provides update on data reviews of imetelstat trials
Read More